Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

British journal of cancer·2026

Same author

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Cancer immunology, immunotherapy : CII·2026

Same author

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Nature medicine·2026

Same author

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.

Nature communications·2026

Same author

BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings.

Cancer research communications·2026

Same journal

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026

Same journal

Patient value over patent value: the mandate for open-source oncology.

Nature reviews. Clinical oncology·2026

Same journal

Cancer burden and control in China: landscape, trends and challenges.

Nature reviews. Clinical oncology·2026

Same journal

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Nature reviews. Clinical oncology·2026

Same journal

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer.

Nature reviews. Clinical oncology·2026

Same journal

Teclistamab monotherapy improves survival in RRMM.

Nature reviews. Clinical oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 16, 2026

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Optimizing CAR T cell therapy for solid tumours: a clinical perspective.

Jiarui Li¹, Chang Liu², Panpan Zhang²

¹Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumors, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.

Nature Reviews. Clinical Oncology

|October 2, 2025

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR) T cell therapy shows promise for solid tumors. This review details strategies to improve CAR T cell efficacy and safety, addressing key challenges for clinical application.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Jan 16, 2026

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment.
Significant challenges remain for its application in solid tumors.

Purpose of the Study:

To review key advances in refining CAR T cell therapy for solid tumors.
To provide practical clinical insights for optimizing efficacy and safety.

Main Methods:

Discussion of target antigen selection for efficacy and toxicity.
Review of strategies including apheresis, manufacturing, lymphodepletion, and delivery methods.
Examination of response evaluation and toxicity management frameworks.

Main Results:

Optimized antigen selection can enhance efficacy while minimizing off-tumor toxicities.
Early intervention and specific delivery methods improve T cell fitness and therapeutic concentration.
Repeat infusions and robust toxicity management are crucial for prolonged effects and safety.

Conclusions:

Systematic optimization of CAR T cell therapy is essential for solid tumors.
Addressing challenges in antigen selection, delivery, and toxicity management will improve patient outcomes.
This review offers a comprehensive guide for advancing CAR T cell therapy in solid malignancies.